Wednesday, 20 Nov 2019

You are here

Lower TNF Inhibitor Persistence in Spondylitis

A claims data analysis shows that only one-third of ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) therapy remain on their initial drug in the 2 years post initiation.

The long-term objectives in managing AS are to improve quality of life, prevent structural damage, and preserve function. Deodhar and colleagues sought to analyze the efficacy of TNFi as measured by persistence, discontinuations, and switching over 2 years of follow up.

This retrospective analysis of adult AS patient data was gathered from the IBM MarketScan Commercial Claims database, specifically looking at patients initiating a TNFi from 01/01/2009 to 12/31/2013. AS patients with other inflammatory diagnoses were excluded. Discontinuation was defined as a ≥ 90-day gap in therapy without starting a new TNFi.  Persistence was defined a no gaps in therapy (≥ 90 days) during the 2-year follow-up.

Analysis of 1372 AS patients (846 males/526 females) found that the most common TNFi started was adalimumab (~44%), followed by etanercept (~41%), infliximab (~10%), golimumab (~4%), and certolizumab (<1%).  The main points of the study included: 

  • Over 2 years only 33% of AS patients (n = 454) persisted on their index TNFi
  • 41% discontinued their index TNFi and did not restart a TNFi
  • 26% stopped their index TNFi and switched to a second TNFi
  • Patients also taking cDMARDs were more likely to persist with their index TNFi  
  • Less likely to persist were females and opioid users 

These retrospective results suggest a higher than expected discontinuation and switching rate amongst AS patients starting a TNFi. 

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Psoriasis Risk Increased with TNF Inhibitors in Juveniles

Children with inflammatory diseases who were treated with tumor necrosis factor (TNF) inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, a single-center retrospective study found.

The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Pain Persists Despite TNF Inhibitor Use

Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain. However, a new claims data study shows that while anti-tumor necrosis factor inhibitor (TNFi) may lower the use of opioids, the reduction is nominal, suggesting that a substantial amount of pain is not adequately addressed by TNFi - a potent anti-inflammatory approach.

Adalimumab and Pregnancy Outcomes

A prospective study of birth outcomes to mothers exposed to adalimumab (ADA) between 2004 and 2016 was conducted by Organization of Teratology Information Specialists (OTIS) Research Center at the University of California San Diego, and showed that ADA exposure was not associated with an increased risk for any of the adverse outcomes examined.

Enbrel Patent Battle Won by Amgen

The ugly, legal, financial underbelly of US biosimilar drug development showed up in court last Friday, when a U.S. judge upheld two of Amgen's patents for Enbrel, thwarting a legal challenge by Novartis/Sandoz over its etanercept-szzs biosimilar, Erelzi. 

Sandoz won FDA approval for their etanercept biosimilar in 2016, but has not been able to market Erelzi because of Amgen’s extended patent protection (till 2029).